Pembrolizumab and dostarlimab are both PD-1 immune checkpoint inhibitors (they block the PD‑1 receptor on T cells to help the immune system attack cancer). So the class effect is similar, but they differ in a few practical ways:
Key differences
1) Indications / approved uses
They’re not used for the exact same cancers or treatment settings.
- Pembrolizumab has broad approvals across many tumor types (e.g., melanoma, lung cancer, head & neck, kidney, bladder, classic Hodgkin lymphoma, some GI cancers, and others) and is used in various combinations (with chemo, etc.) depending on the cancer and biomarker status.
- Dostarlimab has approvals that are more focused—most notably certain endometrial cancers (and settings involving mismatch repair deficiency / MSI‑H/dMMR) and some clinical contexts in other cancers, depending on country and year.
(If you tell me your cancer type and whether it’s MSI‑H/dMMR, I can be more specific.)
2) Dosing schedule
This is a common real-world difference:
- Pembrolizumab: commonly given every 3 weeks or every 6 weeks (depending on dose/indication).
- Dostarlimab: commonly given every 3 weeks initially, then every 6 weeks in some regimens (depending on the protocol/indication).
3) Combination regimens
- Pembrolizumab is often combined with different partners (like chemotherapy) across many cancers.
- Dostarlimab is also used in combinations, but the most common established combinations depend on its approved settings (e.g., specific regimens for endometrial cancer).
4) Drug chemistry / binding
Both target PD‑1, but they’re different monoclonal antibodies, so:
- Their molecular structure and binding characteristics differ.
- In practice, outcomes are often broadly comparable in many settings, but the best choice depends mainly on indication, evidence, and insurance/formulary rather than a major “one is always better” rule.
Side effects (largely similar)
Because they’re both PD‑1 inhibitors, they generally share the same immune-related risks:
- fatigue, rash/itching
- diarrhea/colitis
- hepatitis (liver inflammation)
- thyroid dysfunction
- pneumonitis (lung inflammation)
- less commonly: adrenal issues, kidney inflammation, etc.
So what’s the “main” difference?
The biggest difference is where/when each drug is approved and studied, plus the dosing schedule and regimen. The immune mechanism and general side-effect profile are very similar.
If you share:
- the cancer type,
- stage (or treatment line), and
- whether MSI‑H/dMMR or PD‑L1 is known,
I can tell you which one is typically used and how the regimens differ for that situation.